Rick is the Global Chief Medical Officer and Global Head of Access in the VMLY&Rx Chief Medical and a Board member of the U.K. Biotech company Biotherapy Services Ltd. Rick was also an Executive Leadership Committee member of the Medical Affairs Professional Society (MAPS). Rick has extensive academic, biopharmaceutical industry and global healthcare consulting experience, across a diverse therapeutic range, notably, rare disease, rheumatology and immunology. In addition, his experience is across Anaesthetics, oncology, Dermatology, Ophthalmology, Gastroenterology, and Neurosciences.
Prior to working in WPP , Rick was the International Head of Value & Access at Allergan and Head of function in Allergan’s Medical Affairs and HEPRA division for the EAME region. Prior to working at Allergan, Rick worked in Switzerland for Novartis Pharma as a Global Access Lead on early pipeline development assets in rare diseases. Rick has extensive drug development and commercialization experience from working as Vice President, Consulting at PAREXEL.
Rick has worked on cross functional Global, US and RoW consulting initiatives across a range of therapeutic areas, notably in rare disease, oncology, ophthalmology, neuroscience and immunology. Rick has a particular passion for work in the rare disease space, based on his early academic research work in muscular dystrophy and industry experience in rare diseases with more advanced therapies. Rick has a specific passion for person centred healthcare (PCH) ensuring patients are partners in shaping care, services, guidelines and clinical development. IN addition, Rick has gained experience in the area of Virtualisation of Care (VoC) and specifically how that has been critical for patients with rare diseases during the pandemic which is also driving innovative developments and patient focused advances in digitised healthcare.
Rick received a doctorate in Neuropharmacology from the University of Manchester, UK and has a B.Sc (Hons) degree in Pharmacology from the University of Liverpool, UK and Health Economics, Brunel University, UK